

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1-53. (canceled)

54. (currently amended) An isolated, bloodless, perfused post-partum mammalian placenta that comprises a mammalian cell which is neither fetal nor maternal in origin.

55-59. (canceled)

60. (previously presented) The isolated mammalian placenta of claim 54 which has been perfused or incubated for more than 48 hours.

61. (previously presented) The isolated placenta of claim 54 which has been perfused or incubated for at least about 24 hours.

62. (currently amended) The isolated placenta of claim 54 wherein the solution used to perfuse the placenta ~~contains~~ comprises an anticoagulant solution.

63. (currently amended) The isolated placenta of claim 54 wherein the solution used to perfuse the placenta ~~contains~~ comprises an antimicrobial agent.

64. (currently amended) The isolated placenta of claim 54 wherein the solution used to perfuse the placenta ~~contains~~ comprises growth factors.

65. (previously presented) The isolated placenta of claim 54, wherein the solution used to perfuse said placenta consists essentially of 0.9N saline.

66. (previously presented) The isolated placenta of claim 54, wherein said cell is a stem cell.

67. (previously presented) The placenta of claim 66, wherein said stem cell is an OCT-4⁺, ABC-p⁺ stem cell.

68. (previously presented) The isolated placenta of claim 54, wherein said cell is a mammalian cell.

69. (new) An isolated, bloodless, perfused post-partum mammalian placenta that comprises an exogenous mammalian cell which is neither fetal nor maternal in origin, and wherein said cell is a stem cell that is SSEA3-, SSEA4-, OCT-4+ and ABC-p+.